Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company’s ...

Atossa Genetics (NasdaqCM: ATOS) is a medical diagnostics company focused on the prevention of breast cancer through the development and commercialization of diagnostic tests that can detect ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let ...

・The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease. ・The program could become eligible for a Priority Review Voucher upon future approval.

What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...

Atossa Therapeutics (ATOS 6.18%) has been a top-performing biotech stock rising more than this year. Successful results from a mid-stage clinical trial with a potential new breast cancer treatment ...

Atossa, a clinical-stage biotech that has been popular with investors of late, said it would publish and discuss final data from the phase 2 study of Endoxifen. This is the company's leading pipeline ...

Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.